SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-125350
Filing Date
2024-12-04
Accepted
2024-12-04 07:27:55
Documents
13
Period of Report
2024-12-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430072d1_8k.htm   iXBRL 8-K 24056
  Complete submission text file 0001104659-24-125350.txt   198076

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20241203.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20241203_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20241203_pre.xml EX-101.PRE 22381
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2430072d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 241524804
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)